2017 ECIL[#] GUIDELINES: **Grade AI** RECOMMENDATION

FOR CMV[#] PROPHYLAXIS in R+ ALLOGENEIC HSCT[#] RECIPIENTS[1]

PREVYMIS®

Letermovir

The first and only CMV DNA terminase inhibitor.[2,3]

PREVYMIS® is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).[2]

* Not a real patient. # CMV: Cytomegalovirus; ECIL: European Conference on Infections in Leukaemia; HSCT: haematopoietic stem cell transplantation.

Reference: 1. Ljungman P, De La Camara R, Robin C et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019; Published online May 29, 2019; DOI: 10.1016/S1473-3099(19)30107-0. **2.** Hong Kong Product Circular (PREVYMIS, MSD) **3.** VERGHESE, Priya S.; SCHLEISS, Mark R. Letermovir treatment of human cytomegalovirus infection antiinfective agent. Drugs of the Future, 2013, 38.5: 291.

Selected Safety Information

PREVYMIS® (letermovir, MSD) Film-coated tablets 240 / 480 mg. Concentrate for solution for infusion 240mg / 480mg (IV):

Indication: **PREVYMIS®** is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

Contraindications:

PREVYMIS® is contraindicated in patients: who are hypersensitivity to letermovir or any of the excipients; concomitant use of pimozide or ergot alkaloids (see Drug Interactions). When **PREVYMIS®** is combined with cyclosporine, it is contraindicated to the concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin.

Warnings/Precautions:

Monitoring of CMV DNA on a weekly basis until post-transplant week 14 and subsequently bi-weekly until week 24. In patients with clinically significant CMV DNAemia or disease, stop letermovir prophylaxis and initiate standard-of-care pre-emptive therapy (PET). In patients who are subsequently found positive in CMV DNA test, letermovir prophylaxis could be continued if PET criteria is not met. Excipients: **PREVYMIS®** concentrate for solution for infusion contains sodium. Need consideration to patients on a controlled sodium diet. **PREVYMIS®** film-coated tablet contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product. Effects on ability to drive and use machines: Minor influence on the ability to drive or use machine as fatigue and vertigo have been reported in some patients.

Adverse Reactions:

In clinical trials, the most common adverse reactions(at least 1% and at a frequency > placebo) were: nausea (7.2%), diarrhoea (2.4%), and vomiting (1.9%).

Before prescribing, please consult the full prescribing information.

MSD

MERCK SHARP & DOHME (ASIA) LTD.
27/F Lee Garden Two, 28 Yun Ping Road,
Causeway Bay, Hong Kong.
TEL: (852) 3971 2800 FAX: (852) 2834 0756
Website: www.msd.com.hk